Press Releases Keyword Search Year: 202120202019201820172016201520142013 Jan 17, 2021 Summary ToggleAgios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Jan 11, 2021 Summary ToggleAgios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation Jan 5, 2021 Summary ToggleAgios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 Dec 21, 2020 Summary ToggleAgios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties Dec 7, 2020 Summary ToggleAgios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease Dec 1, 2020 Summary ToggleAgios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Nov 30, 2020 Summary ToggleAgios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias Nov 25, 2020 Summary ToggleAgios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 Nov 12, 2020 Summary ToggleAgios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease Nov 5, 2020 Summary ToggleAgios Reports Business Highlights and Third Quarter 2020 Financial Results Nov 4, 2020 Summary ToggleAgios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting Oct 29, 2020 Summary ToggleAgios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020 Oct 22, 2020 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 Oct 16, 2020 Summary ToggleAgios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia Sep 21, 2020 Summary ToggleAgios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients Sep 8, 2020 Summary ToggleAgios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Aug 27, 2020 Summary ToggleAgios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 Aug 6, 2020 Summary ToggleAgios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 Jul 30, 2020 Summary ToggleAgios Reports Business Highlights and Second Quarter 2020 Financial Results Jul 16, 2020 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020 Jun 17, 2020 Summary ToggleAgios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 Jun 12, 2020 Summary ToggleAgios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty Jun 12, 2020 Summary ToggleAgios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study Jun 12, 2020 Summary ToggleAgios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease Jun 8, 2020 Summary ToggleAgios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia May 29, 2020 Summary ToggleAgios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma May 19, 2020 Summary ToggleAgios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients May 14, 2020 Summary ToggleAgios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress May 13, 2020 Summary ToggleAgios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting May 12, 2020 Summary ToggleAgios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 Apr 30, 2020 Summary ToggleAgios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response Apr 16, 2020 Summary ToggleAgios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020 Mar 30, 2020 Summary ToggleAgios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency Mar 25, 2020 Summary ToggleAgios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb Mar 23, 2020 Summary ToggleAgios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator Feb 18, 2020 Summary ToggleAgios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020 Feb 13, 2020 Summary ToggleAgios Reports Fourth Quarter and Full Year 2019 Financial Results Feb 11, 2020 Summary ToggleAgios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 Jan 30, 2020 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020 Jan 12, 2020 Summary ToggleAgios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones Dec 23, 2019 Summary ToggleAgios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Dec 16, 2019 Summary ToggleAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation Dec 9, 2019 Summary ToggleAgios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency Dec 9, 2019 Summary ToggleAgios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) Dec 8, 2019 Summary ToggleAgios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last